Servier and Treventis Teaming Up to Develop Therapies That Can Circumvent Protein Misfolding

Servier and Treventis Teaming Up to Develop Therapies That Can Circumvent Protein Misfolding
Servier and Treventis will work together on therapies that can circumvent the misfolded proteins involved in Alzheimer’s and other neurodegenerative diseases. The goal is to develop compounds that prevent the brain's accumulation of two faulty proteins associated with the disorders — amyloid beta and tau. Servier is an international pharmaceutical concern led by a non-profit foundation based in France. Treventis is a U.S. company that specializes in developing small molecules that can circumvent the misfolded proteins in the harmful versions of tau and amyloid beta. Under their agreement, Servier will cover the re
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *